Adicet Bio, Inc. Revenue from Related Parties
Adicet Bio, Inc. (ACET) reported Revenue from Related Parties of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2023-05-09
- Adicet Bio, Inc. revenue from related parties for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. revenue from related parties for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. revenue from related parties for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. revenue from related parties for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. revenue from related parties for fiscal 2022 was $24.99M, a 156.83% increase from fiscal 2021.
- Adicet Bio, Inc. revenue from related parties for fiscal 2021 was $9.73M, a 45.65% decline from fiscal 2020.
- Adicet Bio, Inc. revenue from related parties for fiscal 2020 was $17.90M, a 1699.30% increase from fiscal 2019.
- Adicet Bio, Inc. revenue from related parties for fiscal 2019 was $995.00K, a 87.84% decline from fiscal 2018.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-05-09 | $0.00 derived: sum of 3 quarters · filed 2023-05-09 | $0.00 derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $24.99M 10-K · filed 2023-03-15 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $24.99M 10-Q · filed 2022-11-08 | $30.46M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 | $24.99M 10-Q · filed 2022-08-10 | $30.46M derived: sum of 3 quarters · filed 2023-05-09 | $33.89M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | $24.99M 10-Q · filed 2023-05-09 | $30.46M derived: sum of 2 quarters · filed 2023-05-09 | $33.89M derived: sum of 3 quarters · filed 2023-05-09 | $38.70M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $8.90M derived: sum of 2 quarters · filed 2023-03-15 | $13.71M derived: sum of 3 quarters · filed 2023-03-15 | $9.73M 10-K · filed 2023-03-15 |
| 2021-09-30 | $3.43M 10-Q · filed 2022-11-08 | $8.24M derived: sum of 2 quarters · filed 2022-11-08 | $4.26M 10-Q · filed 2022-11-08 | $9.67M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $4.81M 10-Q · filed 2022-08-10 | $833.00K 10-Q · filed 2022-08-10 | $6.24M derived: sum of 3 quarters · filed 2022-08-10 | $9.27M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$3.98M 10-Q · filed 2022-05-12 | $1.43M derived: sum of 2 quarters · filed 2022-05-12 | $4.46M derived: sum of 3 quarters · filed 2022-05-12 | $11.92M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $8.44M derived: sum of 2 quarters · filed 2022-03-15 | $15.90M derived: sum of 3 quarters · filed 2022-03-15 | $17.90M 10-K · filed 2022-03-15 |
| 2020-09-30 | $3.03M 10-Q · filed 2021-11-10 | $10.49M derived: sum of 2 quarters · filed 2021-11-10 | $12.49M 10-Q · filed 2021-11-10 | $14.46M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $7.46M 10-Q · filed 2021-08-12 | $9.46M 10-Q · filed 2021-08-12 | $11.43M derived: sum of 3 quarters · filed 2021-08-12 | $4.39M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-17 | $3.97M derived: sum of 2 quarters · filed 2021-05-17 | -$3.08M derived: sum of 3 quarters · filed 2021-05-17 | |
| 2019-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$5.08M derived: sum of 2 quarters · filed 2021-03-12 | $995.00K 10-K · filed 2021-03-12 | |
| 2019-09-30 | -$7.05M 10-Q · filed 2020-11-05 | -$974.00K 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $8.18M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |